Skip to content

To Investigate Effects of a New Infant Formula in Healthy Term Chinese Infants

A Randomised, Controlled, Double-blind Study to Investigate the Effects of a New Infant Formula on Growth, Safety, and Tolerance in Healthy Term Chinese Infants

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03520764
Enrollment
284
Registered
2018-05-11
Start date
2018-04-03
Completion date
2020-11-09
Last updated
2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Infants

Brief summary

This study investigates the effects of a new infant formula on growth, safety, and tolerance in healthy term Chinese infants. Screening starts after the informed consent is obtained. Infants who are less than or equal to 44 days of age and meeting all eligibility criteria will be enrolled into the study. The total duration of the study is around 12 months which includes 8 study visits. Infants, whose mother has the intention to fully breastfeed her infant at least until 17 weeks of age will be enrolled into the breastfeeding reference group. Infants, whose mother has the intention to fully formula feed her infant as of 44 days of age at the latest, will be randomized to receive either the investigational product or control product until infants reach the age of 17 weeks. After the age of 17 weeks, infants can switch to any feeding and continue be followed up until 12 months of age. Safety, growth and tolerance parameters will be followed and collected throughout the study.

Interventions

DIETARY_SUPPLEMENTNew infant formula with synbiotics

Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.

Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.

Sponsors

Nutricia Early Life Nutrition (Shanghai) Co., Ltd
CollaboratorUNKNOWN
Danone Nutricia
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Intervention group: New infant formula with synbiotics; Control group: Standard infant formula with prebiotics

Eligibility

Sex/Gender
ALL
Age
No minimum to 44 Days
Healthy volunteers
Yes

Inclusion criteria

1. Healthy Chinese term infants ≤ 44 days 2. Birth weight within normal range 3. Head circumference within normal range 4. Fully formula fed by the time of randomization OR fully breastfed and with intention to fully breastfeed until 17 weeks of age

Exclusion criteria

\- The mothers of infants: 1. who are currently participating or will participate in any other (clinical) study involving investigational or marketed products during pregnancy and/or lactation; 2. known to have a significant medical condition that might interfere with the study or known to affect intra-uterine growth, as per investigator's clinical judgement; \- Parents/Legally acceptable representatives/Caregivers of infants: 3. who are incapable to comply with study protocol \- Infants: 4. who have to be fed with a special diet other than standard cow's milk based infant formula; 5. known to have current or previous illnesses/conditions which could interfere with the study products or its outcome parameters 6. known or suspected to have an allergic condition towards cow's milk, soy or fish; 7. with any history of, or current participation in any other study involving investigational or marketed products.

Design outcomes

Primary

MeasureTime frame
Weight gain per day from baseline (g/day)at the age of 17 weeks

Secondary

MeasureTime frame
Parent-reported severity of diarrheafrom baseline until the age of 17 weeks
Parent-reported occurrence of constipationfrom baseline until the age of 17 weeks
Weight gain per day from baseline (g/day) in infant receiving test product compared to breastfed infant.at the age of 17 weeks
Increment per day from baseline on length (mm/day)at the age of 17 weeks
Increment per day from baseline on head circumference (mm/day)at the age of 17 weeks
Increment per day from baseline on mid-upper arm circumference (mm/day)at the age of 17 weeks
Parent-reported severity of constipationfrom baseline until the age of 17 weeks
Z-scores of anthropometric parameters from baseline on lengthfrom baseline until the age of 17 weeks
Z-scores of anthropometric parameters from baseline on head circumferencefrom baseline until the age of 17 weeks
Z-scores of anthropometric parameters from baseline on mid-upper arm circumferencefrom baseline until the age of 17 weeks
Effect on incidence, frequency and severity of (serious) adverse eventsfrom baseline until the age of 17 weeks
Parent-reported occurrence of diarrheafrom baseline until the age of 17 weeks
Z-scores of anthropometric parameters from baseline on weightfrom baseline until the age of 17 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026